MedTrace Logo

A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases

NCT06866080 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2025-07-08

No results posted yet for this study

Summary

This is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory autoimmune diseases.

Conditions

  • Relapsed/Refractory Autoimmune Diseases

Interventions

BIOLOGICAL

LCAR-AIO T cells

Before treatment with LCAR-AIO T cells, subjects will receive a conditioning regimen.

Sponsors & Collaborators

  • Nanjing Legend Biotech Co.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-17
Primary Completion
2025-06-17
Completion
2025-06-17

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06866080 on ClinicalTrials.gov